Asper Biotech

Asper Biotech is a genetic testing company, established in 1999 as a spin-off of a research organization called the Estonian Biocentre.

The company’s technology Arrayed Primer Extension (APEX)  allows simultaneous detection of hundreds of DNA alterations in many different genes. In addition to APEX, Asper Biotech provides testing by Sanger sequencing, NGS sequencing, MLPA analysis and other technologies.

Asper Biotech is an expert at developing state-of-the-art genetic tests for common and rare genetic diseases. Among others, Asper Biotech is specialized in retinal disorders, reproductive medicine and oncology. Asper Ophthalmics testing portfolio includes a comprehensive panel of tests targeting hereditary eye disorders. Asper Oncogenetics and Asper Reprogenetics offer an increasing number of tests aimed respectively to determine cancer predisposition and reproductive problems. Reprogenetical portfolio also includes tests for prenatal diagnostics.

Besides genetic diagnostic services, Asper Biotech offers custom genotyping for international research organizations.

Asper Biotech’s laboratory is an authorized medical laboratory, CLIA (#99D2046227) and ISO 9001:2008 certified. Asper Biotech is participating in the European Molecular Genetics Quality Network (EMQN) quality assessment schemes in order to obtain the external quality control for mutation scanning and improve our testing services.